The federal C.W. Bill Young Cell Transplantation Program helps patients find matching bone marrow and umbilical cord blood donors for transplants used to treat blood cancers, immune disorders, and other diseases. This bill renews funding for the program through fiscal year 2031, raising the annual budget from about $31 million to $33 million starting in 2027. It also changes how the government manages the National Cord Blood Inventory: instead of a fixed target of 150,000 stored units, the Secretary of Health and Human Services would set the goal based on current medical needs and available science. The bill also lets officials move cord blood units to another qualified bank if the original storage facility shuts down, so patients don't lose access to usable donor units.
Transparency & Accountability
- Cord blood inventory target — Fixed 150,000-unit statutory requirement replaced by a Secretary-determined "sufficient supply" standard
Congressional Summary
Stem Cell Therapeutic and Research Reauthorization Act of 2025This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Legislative Subjects
Details
- Congress
- 119th
- Chamber
- House
- Status
- summarized
- Action
- Reported to House
- Action Date
- 2026-07-02
- Date Added
- 2026-07-17
- Source
- Congress.gov →
Like reading a bill in plain English?
We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.